Page 16 - 《中国药房》2025年3期

patients with stage Ⅲ gastric cancer：interim analysis of double blind，phase 3 trial[J]. BMJ，2024，385：e078876.
JACCRO GC-07，a randomized controlled trial[J]. J Clin [28] SENDUR M A，OZDEMIR N，ÖZATLı T，et al. Compari‐
Oncol，2019，37（15）：1296-1304. son the efficacy of second-line modified EOX （epirubi‐
[19] PARK S H，LIM D H，SOHN T S，et al. A randomized cin，oxaliplatin，and capecitabine） and irinotecan，5-fluo‐
phase Ⅲ trial comparing adjuvant single-agent S1，S-1 rouracil，and leucovorin （FOLFIRI） regimens in meta‐
with oxaliplatin，and postoperative chemoradiation with S- static gastric cancer patients that progressed on first-line
1 and oxaliplatin in patients with node-positive gastric modified docetaxel and cisplatin plus fluorouracil （DCF）
cancer after D2 resection：the ARTIST 2 trial[J]. Ann On‐ regimen[J]. Med Oncol，2014，31（9）：153.
col，2021，32（3）：368-374. [29] HALL P S，SWINSON D，CAIRNS D A，et al. Efficacy of
[20] KANG Y K，TERASHIMA M，KIM Y W，et al. Adjuvant reduced-intensity chemotherapy with oxaliplatin and
nivolumab plus chemotherapy versus placebo plus chemo‐ capecitabine on quality of life and cancer control among
therapy for stage Ⅲ gastric or gastro-oesophageal junction older and frail patients with advanced gastroesophageal
cancer after gastrectomy with D2 or more extensive cancer：the GO2 phase 3 randomized clinical trial[J].
lymph-node dissection （ATTRACTION-5） ： a ran‐ JAMA Oncol，2021，7（6）：869-877.
domised，multicentre，double-blind，placebo-controlled， [30] SHITARA K，LORDICK F，BANG Y J，et al. Zolbetux‐
phase 3 trial[J]. Lancet Gastroenterol Hepatol，2024，9 imab plus mFOLFOX6 in patients with CLDN18.2-posi‐
（8）：705-717. tive，HER2-negative，untreated，locally advanced unresec-
[21] YU J，SAEED A. PD-L1 as a predictive biomarker for table or metastatic gastric or gastro-oesophageal junction
pembrolizumab in HER2-positive gastric or gastro- adenocarcinoma （SPOTLIGHT） ：a multicentre，ran‐
esophageal junction adenocarcinoma：a commentary on domised，double-blind，phase 3 trial[J]. Lancet，2023，401
KEYNOTE-811[J]. Chin Clin Oncol，2024，13（4）：59. （10389）：1655-1668.
[22] BANG Y J，VAN CUTSEM E，FEYEREISLOVA A，et al. [31] SHAH M A，SHITARA K，AJANI J A，et al. Zolbetu-
Trastuzumab in combination with chemotherapy versus ximab plus CAPOX in CLDN18.2-positive gastric or gas‐
chemotherapy alone for treatment of HER2-positive ad‐ troesophageal junction adenocarcinoma：the randomized，
vanced gastric or gastro-oesophageal junction cancer phase 3 GLOW trial[J]. Nat Med，2023，29（8）：2133-
（ToGA）：a phase 3，open-label，randomised controlled 2141.
trial[J]. Lancet，2010，376（9742）：687-697. [32] LATHAM A，SRINIVASAN P，KEMEL Y，et al. Micro‐
[23] QIN S K，JI J F，XU R H，et al. Treatment patterns and satellite instability is associated with the presence of
outcomes in Chinese patients with gastric cancer by HER2 Lynch syndrome pan-cancer[J]. J Clin Oncol，2019，37
status：a noninterventional registry study （EVIDENCE） （4）：286-295.
[J]. Oncologist，2021，26（9）：e1567-e1580. [33] SHITARA K，VAN CUTSEM E，BANG Y J，et al. Effi‐
[24] JANJIGIAN Y Y，AJANI J A，MOEHLER M，et al. First- cacy and safety of pembrolizumab or pembrolizumab plus
line nivolumab plus chemotherapy for advanced gastric， chemotherapy vs chemotherapy alone for patients with
gastroesophageal junction，and esophageal adenocarci‐ first-line，advanced gastric cancer：the KEYNOTE-062
noma：3-year follow-up of the phase Ⅲ CheckMate 649 phase 3 randomized clinical trial[J]. JAMA Oncol，2020，6
trial[J]. J Clin Oncol，2024，42（17）：2012-2020. （10）：1571-1580.
[25] XU J M，JIANG H P，PAN Y Y，et al. Sintilimab plus che‐ [34] KAWAKAMI H，HIRONAKA S，ESAKI T，et al. An
motherapy for unresectable gastric or gastroesophageal investigator-initiated phase 2 study of nivolumab plus low-
junction cancer：the ORIENT-16 randomized clinical trial dose ipilimumab as first-line therapy for microsatellite
[J]. JAMA，2023，330（21）：2064-2074. instability-high advanced gastric or esophagogastric junc‐
[26] RHA S Y，OH D Y，YAÑEZ P，et al. Pembrolizumab plus tion cancer （NO LIMIT，WJOG13320G/CA209-7W7）[J].
chemotherapy versus placebo plus chemotherapy for Cancers，2021，13（4）：805.
HER2-negative advanced gastric cancer （KEYNOTE- [35] THUSS-PATIENCE P C，KRETZSCHMAR A，BICHEV
859）：a multicentre，randomised，double-blind，phase 3 D，et al. Survival advantage for irinotecan versus best
trial[J]. Lancet Oncol，2023，24（11）：1181-1195. supportive care as second-line chemotherapy in gastric
[27] QIU M Z，OH D Y，KATO K，et al. Tislelizumab plus che‐ cancer：a randomised phase Ⅲ study of the Arbeitsgemein‐
motherapy versus placebo plus chemotherapy as first line schaft Internistische Onkologie （AIO）[J]. Eur J Cancer，
treatment for advanced gastric or gastro-oesophageal junc‐ 2011，47（15）：2306-2314.
tion adenocarcinoma： RATIONALE-305 randomised， [36] FORD H E，MARSHALL A，BRIDGEWATER J A，et al.

· 266 · China Pharmacy 2025 Vol. 36 No. 3 中国药房 2025年第36卷第3期